Clinical Trial

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Name: A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer — clinical trial record (NCT07757230)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is a phase II clinical trial of SSGJ-612 combined with a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) in patients with hormone receptor (HR)-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Trial Details

NCT Number	NCT07757230
Lead Sponsor	Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions	Metastatic Breast Cancer
Enrollment	87 participants
Start Date	2026-09
Primary Completion	2028-02 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-11